Accomplishments in 2014

The highly productive collaboration between the Sickle Cell Cure Foundation and the EpimedX Limited Liability Company (LLC) continued. Many of the accomplishments listed here were achieved through the efforts and funding of EpimedX.

  • Grants
    • On December 1, the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) awarded a Small Business Innovative Research (SBIR) phase I grant to principal investigator Dr. Robert H. Broyles and EpimedX, LLC. The project title is “Fetal Hemoglobin Induction by Edx-17 to Treat Sickle Cell Disease,” and will continue testing in animals. The NHLBI grant amount is $218,435 and the award number is R43HL12084.
    • On November 1, Dr. Robert Broyles, principal investigator, and EpimedX LLC were awarded a research grant for “A Novel Treatment for Sickle Cell Disease: Dosing Strategy for Maximum Efficacy.” The project will provide important data for making decisions regarding drug delivery methods to human patients. The $162,870 grant was awarded by the Oklahoma Center for the Advancement of Science and Technology (OCAST), and is identified as the Oklahoma Applied Reserach Support (OARS) grant number AR14-056.
  • Planning with the U.S. Food and Drug Administration (FDA)
    • Dr. Carol Curtis spent more than three months preparing 50-page book for the FDA that contains experiment designs, data, and research plans. The book was submitted to the FDA and on October 29 a conference call was held to discuss progress towards the submission of a final application for an Investigational New Drug (IND) for sickle-cell disease.
    • The FDA suggested two additional tests for the research team to perform. The FDA analysts were supportive of continuing development of an IND application. The application process will take more than six months to complete and cost $1.5 to 2-million (including the two additional studies). The application will require several related activities such as: identification of a chemical supplier that follows Good Laboratory Practices and hiring a consultant with expertise in the preparation of an FDA-compliant IND application. The application documentation is expected to be several inches thick when completed.
  • In the Community
    • Dr. Broyles was a finalist for the Researcher of the Year Award from the Oklahoma Bioscience Association, a statewide organization to promote biosciences in Oklahoma.
    • The SCCF was a sponsor of the Ray of Hope Sickle Cell Benefit Dinner and an exhibitor at the Jog, Run or Walk for a Cure events on August 2. These events were coordinated by the Tulsa, Oklahoma organization: The Supporters of Families with Sickle Cell Disease.
    • The SCCF congratulates our collaborators at EpimedX, LLC for being a finalist for the Oklahoma Venture Forum’s “Most Promising New Business of the Year.”
  • In the News
    • Dr. Broyles was featured in The Oklahoman, Business section Sunday August 17 in an article by Jim Stafford titled “Oklahoma Researcher Want to Cure Sickle Cell Disease.”
    • Sarah Terry-Cabo described the Foundation’s research in the article “Grant Supports Research for Sickle Cell Anemia Pill” in the Journal Record, December 9.
    • Dr. Floyd’s life was outlined in the Sunday Oklahoman on December 21 in a Jim Stafford article titled “Kentucky Farm Roots Run Deep in Scientist.”
  • Our Team
    • Dr. Carol Curtis installed a new laboratory instrument from LUOXIS that measures the redox state of blood samples. The new instrument is used to evaluate the effects of our treatment: EdX-17 on the oxidation-reduction potential of blood from treated organisms.
    • A new collaborative relationship was established with Dr. Ashley Baker, Assistant Professor of Pediatrics at the University of Oklahoma Health Sciences Center and Director of the Sickle Cell Clinic.
    • The Institutional Review Board (IRB) protocol for testing of human samples from sickle-cell patients was renewed, as were the Institutional Animal Care and Use Committee (IACUC) protocols for animal testing.
  • Professional Meetings


  1. This is a good development. It means there is still hope for us. Keep it up.
    Thank you.

  2. Williandres Smith, Jr. says

    I would be interested in reading Sarah Terry-Cabo’s article “Grant Supports Research for Sickle Cell Anemia Pill”. Could you provide a link for this document? Also, it appears like you are still in the animal testing phase of this initiative. Do you have any projections regarding when human trials might begin?

    Thank you for your efforts and consideration.

Speak Your Mind